| 產(chǎn)品編號 | bs-1179R |
| 英文名稱 | Rabbit Anti-CTLA4 antibody |
| 中文名稱 | 細胞毒性T細胞抗原-4（CD152）抗體 |
| 別 名 | CD 152; CD152; CD152 antigen; Celiac disease 3; CELIAC3; CTLA 4; CTLA-4; Cytotoxic T cell associated 4; Cytotoxic T lymphocyte associated 4; Cytotoxic T lymphocyte associated antigen 4; Cytotoxic T lymphocyte associated protein 4; Cytotoxic T lymphocyte associated serine esterase 4; Cytotoxic T lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; Cytotoxic T-lymphocyte-associated protein 4; GSE; IDDM12; CD152 isoform; CTLA4_HUMAN; GRD4; ICOS; Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4. |
 |
Specific References (4) | bs-1179R has been referenced in 4 publications.
[IF=4.225] Yu et al. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. (2015) Cancer.Immunol.Immunothe. 64:853-60 IHC ; Human.
[IF=3.532] Zengwei Chen. et al. Quantitative analysis of multiple breast cancer biomarkers using DNA-PAINT. ANAL METHODS-UK. 2022 Aug;: IF ; Human.
[IF=2.976] Peng?Y et al. Sonodynamic therapy improves anti?tumor immune effect by increasing the infiltration of CD8+ T cells and altering tumor blood vessels in murine B16F10 melanoma xenograft. Oncol Rep.?2018 Oct;40(4):2163-2170.? WB ; Mouse.
[IF=1.39] Lan et al. Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. (2018) Oncol.Lett. 15:5093-5097 IHC-P ; Human.
|
| 研究領(lǐng)域 | 腫瘤 免疫學 淋巴細胞 t-淋巴細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat |
| 產(chǎn)品應用 | WB=1:200-1000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 21kDa |
| 檢測分子量 | 33 |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CTLA-4: 141-223/223 <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008] Function: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Subunit: Homodimer; disulfide-linked. Binds to CD80/B7-1 and CD86/B7.2. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Note=Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation. Tissue Specificity: Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. Post-translational modifications: N-glycosylation is important for dimerization. Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. DISEASE: Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Similarity: Contains 1 Ig-like V-type (immunoglobulin-like) domain. SWISS: P16410 Gene ID: 1493 Database links: Entrez Gene: 1493 Human Entrez Gene: 100505288 Mouse Entrez Gene: 12477 Mouse Omim: 123890 Human SwissProt: P16410 Human SwissProt: P09793 Mouse Unigene: 247824 Human Unigene: 390 Mouse Unigene: 10259 Rat CTLA4(細胞毒性T細胞抗原4)，CTLA-4是位于T淋巴細胞膜上的跨膜免疫應答受體分子，CTLA-4對T淋巴細胞的活化具有負調(diào)控作用，有學者認為；CTLA-4可以參與免疫系統(tǒng)的功能，對腫瘤起到有效的抑制作用。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Mouse Spleen tissue lysates
Lane 2: Mouse Thymus tissue lysates
Lane 3: Mouse Lymph node tissue lysates
Lane 4: Rat Spleen tissue lysates
Lane 5: Rat Thymus tissue lysates
Lane 6: Rat Lymph node tissue lysates
Lane 7: Human Raji cell lysates
Lane 8: Human K562 cell lysates
Primary: Anti-CTLA4 (bs-1179R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 21 kDa
Observed band size: 33 kDa
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
